表紙
市場調査レポート

ヒト成長ホルモン (HGH) の米国市場:2015年〜2019年

Human Growth Hormone Market in the US 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 327429
出版日 ページ情報 英文 84 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
ヒト成長ホルモン (HGH) の米国市場:2015年〜2019年 Human Growth Hormone Market in the US 2015-2019
出版日: 2015年03月25日 ページ情報: 英文 84 Pages
概要

米国のヒト成長ホルモン (HGH) 市場は、2014年から2019年にかけて、3.86%のCAGRで拡大することが見込まれています。

当レポートでは、米国におけるヒト成長ホルモン (HGH) 市場の概要や発展因子と課題、主要企業の分析などとともにお届けします。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 ヒト成長ホルモンの概要

  • ヒト成長ホルモン
  • ヒト成長ホルモンの薬理作用
  • ヒト成長ホルモンの治療利用
  • 成長ホルモン分泌不全症
    • 小児成長ホルモン分泌不全症
    • 成人成長ホルモン分泌不全症

第7章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第8章 購入基準

第9章 市場成長因子

第10章 成長因子とその影響

第11章 市場の課題

第12章 成長因子と課題の影響

第13章 市場動向

第14章 動向とその影響

第15章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • M&A
  • 市場シェア分析
    • Novo Nordisk
    • Pfizer
    • Merck Serono
    • F. Hoffmann-La Roche
  • その他の有力ベンダー

第16章 主要ベンダーの分析

  • F. Hoffmann-La Roche Ltd.
  • Merck Serono
  • Novo Nordisk A/S
  • Pfizer

第17章 関連レポート

目次
Product Code: IRTNTR5538

About Human Growth Hormone

Human growth hormone, also known as somatotropin, is a peptide with 191 amino acids and 2 sulfhydryl bridges. It is produced by the anterior pituitary, and it is required to attain normal size for children and adolescents. It also has major effects on lipid and carbohydrate metabolism of an individual. The effects of human growth hormone are mainly mediated by IGF-1 and IGF-2. There are two forms of recombinant human growth hormone approved in the market: Somatropin and Somatrem. Somatropin has 191 amino acids and Somatrem contains 192 amino acids. Growth hormone deficiency can occur either due to a damage to the pituitary or the hypothalamus gland, or can also be acquired genetically. Some of the signs of growth hormone deficiency are adiposity, short stature, and hypoglycemia.

TechNavio's analysts forecast the Human Growth Hormone market in the US to grow at a CAGR of 3.86 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Human Growth Hormone market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of the various human growth hormone drugs available in the US for the treatment of growth hormone deficiency.

TechNavio's report, the Human Growth Hormone Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the Human Growth Hormone market in the US and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Vendors

  • F. Hoffmann-La Roche
  • Merck Serono
  • Novo Nordisk
  • Pfizer

Other Prominent Vendors

  • Eli Lilly
  • Teva Pharmaceutical
  • Novartis
  • Ipsen

Market Driver

  • Demand for Human Growth Hormone
  • For a full, detailed list, view our report

Market Challenge

  • High Cost of Therapy
  • For a full, detailed list, view our report

Market Trend

  • Growing Focus on Needle-free Drug Delivery Devices
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Human Growth Hormone: An Overview

  • 06.1. Human Growth Hormone
  • 06.2. Pharmacological Action of Human Growth Hormone
  • 06.3. Therapeutic Uses of Human Growth Hormone
  • 06.4. Growth Hormone Deficiency
    • 06.4.1. Childhood-onset Growth Hormone Deficiency
    • 06.4.2. Adult-onset Growth Hormone Deficiency

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Buying Criteria

09. Market Growth Drivers

10. Drivers and their Impact

11. Market Challenges

12. Impact of Drivers and Challenges

13. Market Trends

14. Trends and their Impact

15. Vendor Landscape

  • 15.1. Competitive Scenario
    • 15.1.1. Key News
    • 15.1.2. Mergers and Acquisitions
  • 15.2. Market Share Analysis 2014
    • 15.2.1. Novo Nordisk
    • 15.2.2. Pfizer
    • 15.2.3. Merck Serono
    • 15.2.4. F. Hoffmann-La Roche
  • 15.3. Other Prominent Vendors

16. Key Vendor Analysis

  • 16.1. F. Hoffmann-La Roche Ltd.
    • 16.1.1. Key Facts
    • 16.1.2. Business Overview
    • 16.1.3. Business Segmentation
    • 16.1.4. Business Segmentation by Revenue 2012 and 2013
    • 16.1.5. Sales by Geography
    • 16.1.6. Business Strategy
    • 16.1.7. Key Information
    • 16.1.8. SWOT Analysis
  • 16.2. Merck Serono
    • 16.2.1. Key Facts
    • 16.2.2. Business Overview
    • 16.2.3. Geographical Segmentation by Revenue 2013
    • 16.2.4. Business Strategy
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Novo Nordisk A/S
    • 16.3.1. Key Facts
    • 16.3.2. Business Overview
    • 16.3.3. Business Segmentation by Revenue 2013
    • 16.3.4. Business Segmentation by Revenue 2012 and 2013
    • 16.3.5. Sales by Geography
    • 16.3.6. Business Strategy
    • 16.3.7. Key Information
    • 16.3.8. SWOT Analysis
  • 16.4. Pfizer
    • 16.4.1. Key Facts
    • 16.4.2. Business Overview
    • 16.4.3. Business Segmentation by Revenue 2013
    • 16.4.4. Business Segmentation by Revenue 2012 and 2013
    • 16.4.5. Geographical Segmentation by Revenue
    • 16.4.6. Business Strategy
    • 16.4.7. Key Developments
    • 16.4.8. SWOT Analysis

17. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Structure of Human Growth Hormone
  • Exhibit 3: Clinical Uses of Recombinant Human Growth Hormone
  • Exhibit 4: Regulation of Human Growth Hormone and its Effects
  • Exhibit 5: Types of Growth Hormone Deficiency
  • Exhibit 6: Human Growth Hormone Market in US 2014-2019 (US$ million)
  • Exhibit 7: Drivers of Human Growth Hormone Market in US
  • Exhibit 8: NovoFine Needle
  • Exhibit 9: NordiPenMate
  • Exhibit 10: Challenges in Human Growth Hormone Market
  • Exhibit 11: Trends in Human Growth Hormone Market
  • Exhibit 12: Market Share of Vendors 2014
  • Exhibit 13: Comparison of Market Share of Major Drugs 2014 (US$ million)
  • Exhibit 14: YoY Global Revenue and Growth Rate of Norditropin 2012-2014 (US$ million)
  • Exhibit 15: Dosage Strengths of FlexPro
  • Exhibit 16: Dosage Strengths of NordiFlex
  • Exhibit 17: Dosage Strengths of Norditropin NordiLet
  • Exhibit 18: Dosage Strengths of Nordipen
  • Exhibit 19: Diagrammatic Illustration of Nordipen
  • Exhibit 20: Genotropin Miniquick
  • Exhibit 21: Diagrammatic Illustration of Genotropin Miniquick
  • Exhibit 22: Genotropin Mixer
  • Exhibit 23: Parts of Genotropin Mixer
  • Exhibit 24: Genotropin Pen
  • Exhibit 25: Diagrammatic Illustration of Genotropin Pen
  • Exhibit 26: YoY Global Revenue and Growth Rate of Genotropin 2011-2013 (US$ million)
  • Exhibit 27: YoY Global Revenue and Growth Rate of Saizen 2011-2013 (US$ million)
  • Exhibit 28: Diagrammatic Illustration of Click.easy
  • Exhibit 29: Easypod Drug Delivery Device
  • Exhibit 30: Diagrammatic Illustration of Cool.click 2
  • Exhibit 31: One.click Drug Delivery Device
  • Exhibit 32: Serojet Drug Delivery Device
  • Exhibit 33: YoY Global Revenue and Growth Rate of Nutropin 2010-2013 (US$ million)
  • Exhibit 34: Comparison of Global and US Revenue of Nutropin 2012 and 2013 (US$ million)
  • Exhibit 35: Diagrammatic Illustration of Nutropin AQ NuSpin
  • Exhibit 36: Nutropin AQ NuSpin 10
  • Exhibit 37: Nutropin AQ NuSpin 20
  • Exhibit 38: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 39: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 40: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 41: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 42: Merck Serono: Geographical Segmentation by Revenue 2013
  • Exhibit 43: Novo Nordisk A/S: Business Segmentation by Revenue 2013
  • Exhibit 44: Novo Nordisk A/S: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 45: Novo Nordisk A/S: Sales by Geography 2013
  • Exhibit 46: Pfizer: Business Segmentation by Revenue 2013
  • Exhibit 47: Pfizer: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 48: Pfizer: Geographical Segmentation by Revenue 2013
Back to Top